QIAGEN Strengthens QIAstat-Dx With New Barcelona Site
Drive Growth in Infectious Diseases and Precision Medicine Testing
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business.
Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system, which is used for syndromic testing to identify the cause of an illness – especially in the areas of respiratory, gastrointestinal and meningitis / encephalitis conditions.
QIAstat-Dx is also being developed for use in precision medicine, in particular to support the expansion of recent partnerships announced with Eli Lilly and AstraZeneca. In precision medicine applications, QIAstat‑Dx for instance enables specialty care providers to perform genotyping whilst patients undergo routine clinical examination, thus enabling fast decision-making for potential suitability for certain genomically targeted medicines.
The new site builds on the long-standing presence of QIAGEN in the Barcelona area. Teams at the site will include Research & Development, Manufacturing, Sales, Marketing, Quality Assurance and Regulatory Affairs. In addition, it will serve as a center of excellence for R&D in microfluidics, as well as system and assay development.
“QIAstat-Dx demonstrated its value during the COVID-19 pandemic, supporting healthcare providers with rapid syndromic testing and crucial information when time mattered most,” said Thierry Bernard, CEO of QIAGEN. “Now we are building on this success by expanding the QIAstat-Dx pipeline to address a broader spectrum of healthcare needs. This means both expanding the range of pathogens for infectious disease testing as well as developing solutions for other disease areas and precision medicine applications.”
Barcelona provides an ideal location for this expansion, combining access to scientific talent with a robust ecosystem that includes universities, research institutions, start-ups, and well established pharma and life science companies.
QIAGEN can also build on the local expertise in the QIAstat-Dx technology, which was originally developed by a start-up from Barcelona and acquired by QIAGEN in 2018.
Other news from the department business & finance
